At BIOCHINA2026, BiOPartnering offers an unmatched platform to connect with global leaders in biotech, pharma, and investment. With early bird registration ending soon, now is the time to secure your spot and access key decision-makers.

Top Investors Confirmed: Leading venture capital and investment funds including Sequoia China, IDG Capital, Junlian Capital, Hillhouse Ventures, Lilly Asia Ventures, Honghui Fund, and Dinghui Investment will be present, representing the mainstream sources of capital in the biomedicine sector. This is a prime opportunity to explore funding and strategic partnerships.

Global Pharma & Biopharma Participation: Multinational companies such as Bayer, Eli Lilly, Pfizer, Novartis, and Novo Nordisk, along with international biopharma leaders like Celltrion Inc. and Sun Pharma, are joining. Participants gain direct access to executives responsible for business development, licensing, and global collaborations.

Why Attend BiOPartnering 2026?

• Pre-scheduled 1-on-1 meetings with global pharma, biotech, and CDMO leaders
• Direct access to BD, licensing, and investment decision-makers
• Targeted matchmaking across biologics, cell & gene therapy (CGT), vaccines, and advanced technologies
• Insights on emerging trends, regulatory developments, and cross-border opportunities

Early Bird Advantage:

Secure your spot now to lock priority meeting slots and save $150 on registration. Early registration ensures you connect with the right partners before slots fill.

Register now: https://u.morebio.cn/MnEjmeQF

Learn more: https://www.biocn.cn/en/en.html

BiOPartnering at BIOCHINA2026 is where real deals, licensing agreements, and strategic partnerships happen—don’t miss your chance to be part of it.